News – Page 1156 – Endpoints News

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

9 years ago

Another South San Francisco biotech campus takes shape; WSJ: Feds plan charges in Valeant kickback scheme

9 years ago

Grunenthal snags a PhIII-ready orphan drug in Thar Pharma buyout

9 years ago

Amgen, Novartis are racing to regulators with positive PhIII migraine data, but rivals are in hot pursuit

9 years ago

Escalating R&D woes spur fresh M&A chatter for cash-rich Gilead

9 years ago

Two years into an R&D overhaul, GSK plans $250M lab project near Philly for another migration of US staffers

9 years ago

Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?

9 years ago

GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round

9 years ago

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

9 years ago

Sputnik 2.0? Chinese research team first to try CRISPR-Cas9 gene-editing tech on a human

9 years ago

Medicines Co, Alnylam generate positive buzz with evidence of a durable, 6-month LDL response to PCSK9 rival

9 years ago

Low-profile BeyondSpring files for $100M IPO to back cancer work; Erytech hammered after it pulls marketing ...

9 years ago

The Parker Institute aims to speed up cancer R&D, carving out duplicate IRBs at top centers

9 years ago

Roche harnesses a network of academic I/O researchers in $100M global collaborative

9 years ago

AbbVie, Enanta hep C combo looks stellar in CKD study as rivals hustle along the latest cures

9 years ago

Struggling gene therapy pioneer uniQure brings out the ax, chopping programs and staffers in overhaul

9 years ago

Promising or inconclusive? Gilead fields PhII GS-4997 data, triggering more pushback on NASH claims

9 years ago

Puma shares ripped after growing grade 3 diarrhea threat is highlighted in an abstract

9 years ago

Did Merck KGaA’s aging atacicept just fail a PhIIb lupus trial? Well, yes, but…

9 years ago

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

9 years ago

Step 3: Sanofi commits up to $100M to opt-in on Alnylam’s PhIII RNAi hemophilia trial

9 years ago

Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help

9 years ago

Under a short assault, Corbus counterattacks with positive PhII data for systemic sclerosis drug

9 years ago

J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab

9 years ago

First page Previous page 1153 1154 115511561157 1158 1159 Next page Last page